Thyroid Cancer in Adolescents and Young Adults Is Surging Worldwide — But Deaths Aren’t: Strong Evidence of Overdiagnosis from a 185‑Country Analysis
Posted inDiabetes & Endocrinology news Oncology

Thyroid Cancer in Adolescents and Young Adults Is Surging Worldwide — But Deaths Aren’t: Strong Evidence of Overdiagnosis from a 185‑Country Analysis

A 185-country study shows large, sustained increases in thyroid cancer incidence among adolescents and young adults (15–39 years) since the 2000s while mortality remains low and stable — a pattern most consistent with widespread overdiagnosis and overtreatment.
Increased Gestational Weight Gain and Adverse Pregnancy Outcomes After Stopping GLP‑1 Receptor Agonists Prior to or in Early Pregnancy
Posted inDiabetes & Endocrinology news

Increased Gestational Weight Gain and Adverse Pregnancy Outcomes After Stopping GLP‑1 Receptor Agonists Prior to or in Early Pregnancy

In a large retrospective cohort, women who discontinued GLP‑1 receptor agonists shortly before or during early pregnancy had greater gestational weight gain and higher risks of preterm birth, gestational diabetes, and hypertensive disorders compared with propensity‑matched unexposed pregnancies.
Updated Basal Calcitonin Cutoffs Better Predict Extent of Lymph Node Metastasis in Medullary Thyroid Cancer
Posted inDiabetes & Endocrinology news Otorhinolaryngology

Updated Basal Calcitonin Cutoffs Better Predict Extent of Lymph Node Metastasis in Medullary Thyroid Cancer

A multicenter Chinese cohort identifies new preoperative basal calcitonin thresholds (241.9, 693.9, 2378.5, 2787.1 pg/mL) that stratify risk of central, ipsilateral lateral, bilateral/contralateral lateral, and upper mediastinal lymph node metastasis and improve prediction of structural recurrence-free survival versus ATA guidance.
Type 3c Diabetes from Chronic Pancreatitis: Mechanisms, Diagnosis, and Practical Management
Posted inDiabetes & Endocrinology Gastroenterology news

Type 3c Diabetes from Chronic Pancreatitis: Mechanisms, Diagnosis, and Practical Management

This article synthesizes current understanding of type 3c diabetes (T3cDM) caused by chronic pancreatitis—covering pathophysiology (islet loss, exocrine insufficiency, altered incretin and hepatic/peripheral insulin sensitivity), diagnostic approaches, and pragmatic treatment strategies including enzyme replacement and tailored glycemic therapy.
Stepped Care Plus Cash Incentives Cuts 3‑Year Diabetes Incidence in Multiethnic Asian Prediabetes Cohort
Posted inAI Diabetes & Endocrinology news

Stepped Care Plus Cash Incentives Cuts 3‑Year Diabetes Incidence in Multiethnic Asian Prediabetes Cohort

The Pre-DICTED randomized trial found a stepped-care diabetes prevention program augmented with financial incentives reduced 3‑year diabetes conversion (34.8% vs 47.3%; adjusted RR 0.74), with metformin added for persistent high-risk participants and modest increased adverse events largely from GI symptoms.
AI-Derived Body Composition Analysis Unveils Muscle Volume, Metformin-Associated Adipose Effects, and the Obesity Paradox in NSCLC: Clinical and Molecular Insights
Posted inClinical Updates Diabetes & Endocrinology Gastroenterology news

AI-Derived Body Composition Analysis Unveils Muscle Volume, Metformin-Associated Adipose Effects, and the Obesity Paradox in NSCLC: Clinical and Molecular Insights

AI-driven analysis identifies muscle volume as a robust predictor of survival in NSCLC, highlights metformin-modulated adipose effects, and elucidates molecular links to the obesity paradox, informing personalized prognosis beyond BMI.
SGLT2 Inhibitors Linked to Lower Fibrosis Progression than DPP‑4 Inhibitors in MASLD with T2DM: Target‑Trial Emulation of Real‑World Cohorts
Posted inDiabetes & Endocrinology Gastroenterology news

SGLT2 Inhibitors Linked to Lower Fibrosis Progression than DPP‑4 Inhibitors in MASLD with T2DM: Target‑Trial Emulation of Real‑World Cohorts

A multicenter target‑trial emulation found SGLT2 inhibitor initiation was associated with a 22% lower risk of progression to advanced fibrosis (confirmed FIB‑4 >2.67) versus DPP‑4 inhibitors in adults with MASLD and T2DM and low‑to‑intermediate baseline fibrosis.
Pemvidutide Produces Rapid Reductions in Liver Fat and AI‑Quantified Fibrosis in Early Phase Trials — Promise and Unanswered Questions
Posted inDiabetes & Endocrinology Gastroenterology news

Pemvidutide Produces Rapid Reductions in Liver Fat and AI‑Quantified Fibrosis in Early Phase Trials — Promise and Unanswered Questions

Pemvidutide, a dual GLP‑1/glucagon receptor agonist, reduced liver fat markedly and produced small but statistically significant reductions in AI‑quantified fibrosis over 24 weeks in phase 2 studies, but longer trials with clinical endpoints are needed to establish meaningful benefit.
Preoperative HbA1c Identifies Hidden Risk: Dysglycemia Predicts Worse 30‑Day Outcomes After General Surgery
Posted inDiabetes & Endocrinology General Surgery news

Preoperative HbA1c Identifies Hidden Risk: Dysglycemia Predicts Worse 30‑Day Outcomes After General Surgery

A large multicenter cohort shows that both diagnosed and previously unrecognized diabetes (by HbA1c) are common in general surgery patients and independently linked to higher 30‑day complications, readmissions, and mortality—supporting routine preoperative HbA1c assessment and individualized perioperative glycemic strategies.
Metformin Exposure Associated with Up to 81% Lower 30‑Day Mortality After Cardiac Surgery in T2DM: A Critical Appraisal of AHA 2025 MIMIC‑IV Cohort Findings
Posted inCardiology Diabetes & Endocrinology news

Metformin Exposure Associated with Up to 81% Lower 30‑Day Mortality After Cardiac Surgery in T2DM: A Critical Appraisal of AHA 2025 MIMIC‑IV Cohort Findings

A retrospective MIMIC‑IV cohort presented at AHA 2025 found perioperative metformin exposure in T2DM patients undergoing cardiac surgery associated with markedly lower 30‑, 90‑ and 360‑day mortality. Results are compelling but observational—randomized trials are needed to confirm causality and define perioperative use.